Short Interest in Revelation Biosciences, Inc. (NASDAQ:REVB) Increases By 87.5%

Revelation Biosciences, Inc. (NASDAQ:REVB) saw a significant increase in short interest in May. As of May 15th, there was short interest totaling 34,510 shares, an increase of 87.5% from the April 30th total of 18,409 shares. Approximately 0.9% of the company’s stock are sold short. Based on an average trading volume of 81,197 shares, the short-interest ratio is currently 0.4 days.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Armistice Capital LLC lifted its stake in shares of Revelation Biosciences by 442.8% during the 4th quarter. Armistice Capital LLC now owns 434,272 shares of the company’s stock valued at $347,000 after buying an additional 354,272 shares in the last quarter. Geode Capital Management LLC purchased a new stake in shares of Revelation Biosciences during the 4th quarter valued at approximately $27,000. Finally, Sabby Management LLC lifted its stake in shares of Revelation Biosciences by 192.5% during the 4th quarter. Sabby Management LLC now owns 605,702 shares of the company’s stock valued at $484,000 after buying an additional 398,651 shares in the last quarter. 12.80% of the stock is owned by institutional investors.

Revelation Biosciences Stock Performance

Shares of REVB stock opened at $1.04 on Thursday. Revelation Biosciences has a 52-week low of $0.88 and a 52-week high of $12.88. The company has a 50-day simple moving average of $1.12 and a two-hundred day simple moving average of $2.12. The company has a market capitalization of $4.07 million, a price-to-earnings ratio of -0.03 and a beta of -0.09.

Revelation Biosciences (NASDAQ:REVB) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($2.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.15) by ($1.56). On average, sell-side analysts forecast that Revelation Biosciences will post -4.99 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of Revelation Biosciences from a “sell (e)” rating to a “sell (e+)” rating in a research report on Tuesday. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of “Sell”.

About Revelation Biosciences

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.